Understand the source comparison
Adamax Blood Work Labs Check Before After — Comparison Table
This table shows how key biomarkers typically shift from baseline to 8–12 weeks post-protocol for common peptide categories, along with professional assessment criteria. IGF-1 (ng/mL) Age-adjusted normal (e.g., 150–250 for age 30–40) 40–90% elevation from base
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- This table shows how key biomarkers typically shift from baseline to 8–12 weeks post-protocol for common peptide categories, along with professional assessment criteria.
- IGF-1 (ng/mL)
- Age-adjusted normal (e.g., 150–250 for age 30–40)
- 40–90% elevation from baseline
- ↑
- >400 ng/mL warrants dose reduction
- Elevation confirms GH secretagogue efficacy; exceeding 400 ng/mL increases risk without added benefit
- Fasting Glucose (mg/dL)
- 70–99 (normal)
- Should remain <100
- → or slight ↑
- ≥100 mg/dL indicates impaired fasting glucose
- GH can transiently raise glucose; sustained elevation requires protocol adjustment
- ALT/AST (U/L)
- <40 / <35 (normal)
- Should remain within 10% of baseline
- →
- ALT >60 or AST >50 requires investigation
- Transient elevation during dose escalation is common; sustained elevation suggests hepatic stress
- Total Testosterone (ng/dL, males)
- 300–1000 (normal)
- Should remain stable or increase slightly
- → or ↑
- <300 ng/dL indicates suppression
- Some peptides suppress endogenous production; significant drop requires intervention
- SHBG (nmol/L)
- 10–57 (males), 18–114 (females)
- Should remain stable
- Significant deviation alters free hormone availability
- Changes in SHBG affect bioavailable testosterone/estradiol even if total levels are stable
- Hemoglobin A1c (%)
- <5.7 (normal)
- Should remain <5.7
- ≥5.7% indicates prediabetes
- Long-term glucose control marker; more reliable than single fasting glucose tests